Jeri Forster
Concepts (495)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Veterans | 79 | 2025 | 1466 | 7.740 |
Why?
| | Suicidal Ideation | 22 | 2025 | 522 | 2.810 |
Why?
| | Brain Injuries, Traumatic | 16 | 2025 | 355 | 2.750 |
Why?
| | Suicide | 16 | 2024 | 645 | 2.660 |
Why?
| | Brain Concussion | 17 | 2025 | 573 | 1.910 |
Why?
| | Brain Injuries | 10 | 2022 | 494 | 1.680 |
Why?
| | Sex Offenses | 7 | 2023 | 193 | 1.610 |
Why?
| | Military Personnel | 12 | 2025 | 544 | 1.590 |
Why?
| | Stress Disorders, Post-Traumatic | 18 | 2025 | 842 | 1.450 |
Why?
| | United States Department of Veterans Affairs | 20 | 2025 | 674 | 1.320 |
Why?
| | Sleep Initiation and Maintenance Disorders | 7 | 2024 | 165 | 1.260 |
Why?
| | Suicide, Attempted | 10 | 2021 | 373 | 1.240 |
Why?
| | Arthroplasty, Replacement, Knee | 9 | 2025 | 359 | 1.090 |
Why?
| | Activities of Daily Living | 9 | 2025 | 413 | 1.090 |
Why?
| | United States | 62 | 2025 | 14691 | 1.030 |
Why?
| | Occupational Therapy | 6 | 2025 | 100 | 1.020 |
Why?
| | Mental Disorders | 10 | 2025 | 1070 | 1.000 |
Why?
| | Post-Concussion Syndrome | 5 | 2024 | 174 | 0.970 |
Why?
| | Self-Injurious Behavior | 4 | 2020 | 129 | 0.940 |
Why?
| | Home Care Services | 8 | 2024 | 257 | 0.930 |
Why?
| | Physical Therapy Modalities | 10 | 2024 | 308 | 0.930 |
Why?
| | Middle Aged | 77 | 2025 | 33228 | 0.860 |
Why?
| | Skilled Nursing Facilities | 6 | 2023 | 140 | 0.830 |
Why?
| | Humans | 153 | 2025 | 136764 | 0.810 |
Why?
| | Female | 108 | 2025 | 72787 | 0.800 |
Why?
| | Patient Discharge | 13 | 2025 | 894 | 0.790 |
Why?
| | Aftercare | 2 | 2021 | 207 | 0.780 |
Why?
| | Male | 105 | 2025 | 67309 | 0.780 |
Why?
| | Aged | 52 | 2025 | 23794 | 0.760 |
Why?
| | Psychometrics | 7 | 2024 | 719 | 0.740 |
Why?
| | Sexual Harassment | 3 | 2016 | 27 | 0.730 |
Why?
| | Adult | 71 | 2025 | 37630 | 0.730 |
Why?
| | Resistance Training | 4 | 2024 | 163 | 0.680 |
Why?
| | Embolism, Fat | 1 | 2020 | 11 | 0.680 |
Why?
| | Hospitalization | 11 | 2025 | 2183 | 0.640 |
Why?
| | Social Support | 1 | 2024 | 616 | 0.640 |
Why?
| | Health Services Accessibility | 5 | 2025 | 978 | 0.580 |
Why?
| | Exercise Therapy | 7 | 2025 | 436 | 0.540 |
Why?
| | Cross-Sectional Studies | 18 | 2025 | 5423 | 0.530 |
Why?
| | Firearms | 1 | 2022 | 376 | 0.510 |
Why?
| | Retrospective Studies | 32 | 2025 | 15504 | 0.500 |
Why?
| | Death | 1 | 2016 | 119 | 0.490 |
Why?
| | Depressive Disorder, Major | 3 | 2025 | 361 | 0.480 |
Why?
| | Neuropsychological Tests | 4 | 2019 | 1022 | 0.480 |
Why?
| | Sleep Apnea, Obstructive | 3 | 2024 | 291 | 0.480 |
Why?
| | Multiple Sclerosis | 4 | 2024 | 455 | 0.480 |
Why?
| | Patient Dropouts | 2 | 2015 | 67 | 0.470 |
Why?
| | Muscle Strength | 6 | 2024 | 317 | 0.460 |
Why?
| | Arthroplasty, Replacement, Hip | 3 | 2024 | 177 | 0.460 |
Why?
| | Risk Factors | 17 | 2024 | 10326 | 0.450 |
Why?
| | Multimorbidity | 2 | 2025 | 47 | 0.450 |
Why?
| | Osteoarthritis, Knee | 3 | 2025 | 254 | 0.430 |
Why?
| | Executive Function | 3 | 2017 | 440 | 0.430 |
Why?
| | Health Personnel | 4 | 2024 | 701 | 0.420 |
Why?
| | Gait | 3 | 2025 | 296 | 0.420 |
Why?
| | Walking Speed | 3 | 2024 | 45 | 0.410 |
Why?
| | Fear | 1 | 2016 | 338 | 0.410 |
Why?
| | Veterans Health | 6 | 2023 | 185 | 0.400 |
Why?
| | Burnout, Professional | 3 | 2024 | 440 | 0.390 |
Why?
| | Biofeedback, Psychology | 2 | 2025 | 37 | 0.390 |
Why?
| | Biometry | 1 | 2011 | 70 | 0.360 |
Why?
| | Probability | 1 | 2011 | 304 | 0.350 |
Why?
| | Recovery of Function | 7 | 2025 | 652 | 0.340 |
Why?
| | Sleep Wake Disorders | 3 | 2022 | 283 | 0.340 |
Why?
| | Young Adult | 15 | 2025 | 13129 | 0.330 |
Why?
| | Sex Factors | 6 | 2025 | 2060 | 0.330 |
Why?
| | Physical and Rehabilitation Medicine | 2 | 2021 | 32 | 0.320 |
Why?
| | Referral and Consultation | 1 | 2015 | 780 | 0.320 |
Why?
| | Patient Readmission | 4 | 2024 | 694 | 0.320 |
Why?
| | Walking | 4 | 2024 | 523 | 0.320 |
Why?
| | Aged, 80 and over | 15 | 2024 | 7585 | 0.320 |
Why?
| | Anti-HIV Agents | 3 | 2015 | 775 | 0.310 |
Why?
| | Exercise | 4 | 2021 | 2043 | 0.300 |
Why?
| | Electric Impedance | 2 | 2019 | 107 | 0.300 |
Why?
| | Models, Statistical | 2 | 2015 | 667 | 0.290 |
Why?
| | Depression | 7 | 2024 | 1395 | 0.290 |
Why?
| | Edema | 2 | 2019 | 129 | 0.290 |
Why?
| | Healthcare Disparities | 2 | 2025 | 649 | 0.290 |
Why?
| | Chronic Pain | 2 | 2024 | 259 | 0.280 |
Why?
| | Risk | 6 | 2023 | 908 | 0.280 |
Why?
| | Walk Test | 2 | 2024 | 76 | 0.280 |
Why?
| | Factor Analysis, Statistical | 5 | 2024 | 283 | 0.270 |
Why?
| | Lower Extremity | 3 | 2024 | 423 | 0.270 |
Why?
| | September 11 Terrorist Attacks | 2 | 2025 | 32 | 0.270 |
Why?
| | Pilot Projects | 8 | 2024 | 1692 | 0.270 |
Why?
| | Patient Compliance | 4 | 2024 | 577 | 0.260 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2024 | 1462 | 0.260 |
Why?
| | Anxiety | 4 | 2024 | 1031 | 0.260 |
Why?
| | Prospective Studies | 7 | 2023 | 7572 | 0.250 |
Why?
| | Occupational Diseases | 2 | 2019 | 156 | 0.250 |
Why?
| | Longitudinal Studies | 8 | 2024 | 2829 | 0.250 |
Why?
| | HIV Infections | 7 | 2015 | 2828 | 0.240 |
Why?
| | Feasibility Studies | 7 | 2025 | 951 | 0.240 |
Why?
| | Subacute Care | 3 | 2021 | 79 | 0.240 |
Why?
| | Postural Balance | 2 | 2018 | 216 | 0.240 |
Why?
| | Disability Evaluation | 2 | 2020 | 290 | 0.240 |
Why?
| | Comorbidity | 7 | 2025 | 1614 | 0.230 |
Why?
| | Social Participation | 1 | 2025 | 27 | 0.230 |
Why?
| | Art Therapy | 1 | 2024 | 20 | 0.230 |
Why?
| | Medicare | 5 | 2021 | 758 | 0.220 |
Why?
| | Adolescent | 13 | 2024 | 21382 | 0.220 |
Why?
| | Decision Making | 3 | 2024 | 898 | 0.220 |
Why?
| | Telerehabilitation | 1 | 2025 | 37 | 0.220 |
Why?
| | Enterobacter cloacae | 1 | 2024 | 5 | 0.220 |
Why?
| | Knee Joint | 2 | 2025 | 409 | 0.220 |
Why?
| | Gastrointestinal Microbiome | 2 | 2023 | 697 | 0.220 |
Why?
| | Osteoarthritis, Hip | 1 | 2024 | 45 | 0.220 |
Why?
| | Self Report | 6 | 2019 | 822 | 0.220 |
Why?
| | Patient Health Questionnaire | 1 | 2024 | 37 | 0.220 |
Why?
| | Seasonal Affective Disorder | 1 | 2023 | 11 | 0.210 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2024 | 83 | 0.210 |
Why?
| | Enterobacteriaceae Infections | 1 | 2024 | 43 | 0.210 |
Why?
| | Luteinizing Hormone | 2 | 2023 | 185 | 0.210 |
Why?
| | Inpatients | 4 | 2025 | 496 | 0.200 |
Why?
| | Outpatients | 4 | 2025 | 393 | 0.200 |
Why?
| | Frail Elderly | 1 | 2024 | 131 | 0.200 |
Why?
| | Iraq War, 2003-2011 | 5 | 2024 | 127 | 0.200 |
Why?
| | Health Services Needs and Demand | 2 | 2021 | 271 | 0.190 |
Why?
| | Antidepressive Agents | 1 | 2024 | 235 | 0.190 |
Why?
| | Geriatric Assessment | 2 | 2024 | 224 | 0.190 |
Why?
| | Case-Control Studies | 6 | 2022 | 3540 | 0.190 |
Why?
| | Residence Characteristics | 1 | 2025 | 349 | 0.180 |
Why?
| | Ownership | 1 | 2022 | 93 | 0.180 |
Why?
| | Prevalence | 5 | 2021 | 2711 | 0.180 |
Why?
| | Psychological Trauma | 1 | 2022 | 55 | 0.180 |
Why?
| | Age Factors | 3 | 2024 | 3284 | 0.180 |
Why?
| | Nerve Compression Syndromes | 1 | 2021 | 21 | 0.180 |
Why?
| | Health Knowledge, Attitudes, Practice | 3 | 2024 | 1320 | 0.180 |
Why?
| | Nutritional Status | 1 | 2024 | 344 | 0.180 |
Why?
| | Cross Infection | 1 | 2024 | 252 | 0.180 |
Why?
| | Reproducibility of Results | 5 | 2022 | 3264 | 0.180 |
Why?
| | Radiculopathy | 1 | 2021 | 35 | 0.180 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2016 | 390 | 0.180 |
Why?
| | Ambulatory Care | 1 | 2025 | 539 | 0.180 |
Why?
| | Psychiatric Status Rating Scales | 3 | 2018 | 547 | 0.170 |
Why?
| | Stroke Rehabilitation | 1 | 2021 | 42 | 0.170 |
Why?
| | Frailty | 1 | 2024 | 169 | 0.170 |
Why?
| | Physical Abuse | 1 | 2021 | 39 | 0.170 |
Why?
| | Glasgow Outcome Scale | 1 | 2020 | 9 | 0.170 |
Why?
| | Women | 1 | 2021 | 50 | 0.170 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2021 | 128 | 0.170 |
Why?
| | Survivors | 2 | 2021 | 487 | 0.170 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2021 | 88 | 0.160 |
Why?
| | Internship and Residency | 2 | 2021 | 1132 | 0.160 |
Why?
| | Risk Assessment | 7 | 2020 | 3432 | 0.160 |
Why?
| | Single-Blind Method | 4 | 2024 | 282 | 0.160 |
Why?
| | Substance-Related Disorders | 2 | 2023 | 1069 | 0.160 |
Why?
| | Mobility Limitation | 1 | 2020 | 61 | 0.160 |
Why?
| | Value of Life | 2 | 2016 | 17 | 0.160 |
Why?
| | Glasgow Coma Scale | 1 | 2020 | 184 | 0.160 |
Why?
| | Students, Health Occupations | 1 | 2020 | 34 | 0.160 |
Why?
| | Arthroplasty, Replacement | 1 | 2020 | 45 | 0.160 |
Why?
| | Competency-Based Education | 1 | 2020 | 73 | 0.150 |
Why?
| | Myofascial Pain Syndromes | 1 | 2019 | 12 | 0.150 |
Why?
| | Medicine | 1 | 2021 | 121 | 0.150 |
Why?
| | Electromyography | 1 | 2021 | 401 | 0.150 |
Why?
| | Pelvic Pain | 1 | 2019 | 33 | 0.150 |
Why?
| | Transitional Care | 1 | 2019 | 40 | 0.150 |
Why?
| | Speech Discrimination Tests | 1 | 2018 | 3 | 0.150 |
Why?
| | Mental Health Services | 4 | 2024 | 416 | 0.150 |
Why?
| | Drug Overdose | 1 | 2023 | 345 | 0.150 |
Why?
| | Physical Therapists | 1 | 2019 | 62 | 0.140 |
Why?
| | Sense of Coherence | 1 | 2018 | 11 | 0.140 |
Why?
| | Health Services for the Aged | 1 | 2019 | 80 | 0.140 |
Why?
| | Hope | 1 | 2018 | 22 | 0.140 |
Why?
| | Afghan Campaign 2001- | 4 | 2022 | 132 | 0.140 |
Why?
| | Professional Role | 1 | 2019 | 165 | 0.140 |
Why?
| | Eye Movements | 1 | 2018 | 67 | 0.140 |
Why?
| | Combat Disorders | 1 | 2017 | 37 | 0.140 |
Why?
| | Drug Packaging | 1 | 2017 | 45 | 0.130 |
Why?
| | Socioeconomic Factors | 3 | 2020 | 1282 | 0.130 |
Why?
| | Prefrontal Cortex | 2 | 2017 | 304 | 0.130 |
Why?
| | Speech Perception | 1 | 2018 | 82 | 0.130 |
Why?
| | Educational Measurement | 1 | 2020 | 281 | 0.130 |
Why?
| | Personality Assessment | 1 | 2017 | 84 | 0.130 |
Why?
| | Joint Instability | 1 | 2019 | 167 | 0.130 |
Why?
| | Visual Perception | 1 | 2018 | 160 | 0.130 |
Why?
| | Parkinson Disease | 1 | 2022 | 490 | 0.130 |
Why?
| | Range of Motion, Articular | 3 | 2025 | 391 | 0.130 |
Why?
| | Pain Measurement | 1 | 2019 | 521 | 0.130 |
Why?
| | Depressive Disorder | 2 | 2018 | 379 | 0.130 |
Why?
| | War Exposure | 1 | 2016 | 12 | 0.130 |
Why?
| | Nelfinavir | 1 | 2016 | 9 | 0.130 |
Why?
| | Patient Safety | 1 | 2020 | 308 | 0.130 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2822 | 0.130 |
Why?
| | Vaccines, DNA | 2 | 2008 | 32 | 0.130 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 1996 | 44 | 0.130 |
Why?
| | Lopinavir | 1 | 2016 | 30 | 0.130 |
Why?
| | Hypertension, Portal | 1 | 1996 | 64 | 0.120 |
Why?
| | Atazanavir Sulfate | 1 | 2016 | 41 | 0.120 |
Why?
| | HIV-1 | 3 | 2008 | 863 | 0.120 |
Why?
| | Pharmacovigilance | 1 | 2015 | 23 | 0.120 |
Why?
| | Attitude to Death | 1 | 2016 | 68 | 0.120 |
Why?
| | AIDS Vaccines | 2 | 2008 | 52 | 0.120 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2016 | 83 | 0.120 |
Why?
| | HIV Protease Inhibitors | 1 | 2016 | 69 | 0.120 |
Why?
| | Microbiota | 1 | 2023 | 762 | 0.120 |
Why?
| | Ritonavir | 1 | 2016 | 74 | 0.120 |
Why?
| | Child | 8 | 2024 | 21822 | 0.120 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2008 | 173 | 0.120 |
Why?
| | Actigraphy | 1 | 2016 | 110 | 0.120 |
Why?
| | Clinical Competence | 2 | 2020 | 1094 | 0.120 |
Why?
| | Gene Dosage | 1 | 2016 | 140 | 0.120 |
Why?
| | Medical Records | 1 | 2016 | 174 | 0.120 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 73 | 0.120 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 77 | 0.120 |
Why?
| | Hearing Loss | 1 | 2018 | 220 | 0.120 |
Why?
| | Warfare | 1 | 2015 | 68 | 0.120 |
Why?
| | Medication Errors | 1 | 2015 | 95 | 0.120 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2008 | 179 | 0.110 |
Why?
| | Exome | 1 | 2016 | 230 | 0.110 |
Why?
| | Interviews as Topic | 3 | 2025 | 772 | 0.110 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 113 | 0.110 |
Why?
| | Surveys and Questionnaires | 6 | 2018 | 5742 | 0.110 |
Why?
| | Videotape Recording | 1 | 1994 | 35 | 0.110 |
Why?
| | Thalamus | 1 | 2015 | 107 | 0.110 |
Why?
| | Violence | 1 | 2017 | 257 | 0.110 |
Why?
| | Dizziness | 3 | 2019 | 82 | 0.110 |
Why?
| | Cohort Studies | 6 | 2021 | 5701 | 0.110 |
Why?
| | Risk-Taking | 2 | 2017 | 347 | 0.110 |
Why?
| | Complementary Therapies | 1 | 2014 | 88 | 0.110 |
Why?
| | Ozone | 3 | 2000 | 131 | 0.110 |
Why?
| | Cerebellum | 1 | 2015 | 224 | 0.110 |
Why?
| | Ambulatory Surgical Procedures | 1 | 1994 | 65 | 0.110 |
Why?
| | Medication Adherence | 1 | 2017 | 466 | 0.100 |
Why?
| | Liver Diseases | 1 | 1996 | 311 | 0.100 |
Why?
| | Injury Severity Score | 1 | 2015 | 521 | 0.100 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2015 | 182 | 0.100 |
Why?
| | Iraq | 2 | 2024 | 53 | 0.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 250 | 0.100 |
Why?
| | Afghanistan | 2 | 2024 | 71 | 0.100 |
Why?
| | Hypertension | 1 | 2022 | 1284 | 0.100 |
Why?
| | Pandemics | 1 | 2021 | 1613 | 0.100 |
Why?
| | Thinness | 1 | 2013 | 91 | 0.100 |
Why?
| | Athletic Injuries | 1 | 2019 | 526 | 0.100 |
Why?
| | Emotions | 1 | 2018 | 545 | 0.100 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 992 | 0.100 |
Why?
| | Fatigue | 3 | 2019 | 327 | 0.100 |
Why?
| | Decision Support Systems, Clinical | 1 | 2015 | 223 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2025 | 10744 | 0.090 |
Why?
| | Preoperative Care | 1 | 1994 | 356 | 0.090 |
Why?
| | Quality Improvement | 1 | 2020 | 1163 | 0.090 |
Why?
| | Time Factors | 5 | 2021 | 6806 | 0.090 |
Why?
| | Biomechanical Phenomena | 2 | 2025 | 806 | 0.090 |
Why?
| | Interpersonal Relations | 1 | 2015 | 396 | 0.090 |
Why?
| | Quadriceps Muscle | 2 | 2024 | 132 | 0.090 |
Why?
| | Wounds and Injuries | 1 | 2018 | 755 | 0.090 |
Why?
| | Tertiary Care Centers | 2 | 2024 | 159 | 0.090 |
Why?
| | Mental Health | 3 | 2023 | 716 | 0.090 |
Why?
| | Attitude to Health | 1 | 1994 | 437 | 0.090 |
Why?
| | HIV | 1 | 2011 | 234 | 0.080 |
Why?
| | Hospitals, Veterans | 3 | 2019 | 249 | 0.080 |
Why?
| | Postoperative Complications | 2 | 2019 | 2639 | 0.080 |
Why?
| | Bayes Theorem | 2 | 2022 | 404 | 0.080 |
Why?
| | Glucose | 1 | 2015 | 1019 | 0.080 |
Why?
| | Epilepsy | 1 | 2014 | 331 | 0.080 |
Why?
| | Receptors, CXCR4 | 2 | 2007 | 86 | 0.080 |
Why?
| | Cross-Over Studies | 2 | 2025 | 562 | 0.080 |
Why?
| | Cognition | 3 | 2023 | 1146 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 1994 | 761 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 3555 | 0.080 |
Why?
| | Adipose Tissue | 1 | 2013 | 630 | 0.080 |
Why?
| | Analysis of Variance | 3 | 2019 | 1316 | 0.080 |
Why?
| | Oxidants, Photochemical | 2 | 1999 | 8 | 0.070 |
Why?
| | Proportional Hazards Models | 2 | 2025 | 1261 | 0.070 |
Why?
| | Length of Stay | 1 | 2014 | 1205 | 0.070 |
Why?
| | Seasons | 3 | 2000 | 544 | 0.070 |
Why?
| | Attitude of Health Personnel | 1 | 2016 | 1163 | 0.070 |
Why?
| | Colorado | 4 | 2023 | 4518 | 0.070 |
Why?
| | RNA, Viral | 1 | 2011 | 654 | 0.070 |
Why?
| | Incidence | 2 | 2025 | 2792 | 0.070 |
Why?
| | Trauma Severity Indices | 2 | 2019 | 106 | 0.070 |
Why?
| | Qualitative Research | 2 | 2024 | 1366 | 0.070 |
Why?
| | Parents | 1 | 2015 | 1340 | 0.070 |
Why?
| | Interferon-gamma | 2 | 2008 | 788 | 0.070 |
Why?
| | Prion Diseases | 1 | 2006 | 15 | 0.070 |
Why?
| | alpha-Defensins | 1 | 2006 | 10 | 0.070 |
Why?
| | Creutzfeldt-Jakob Syndrome | 1 | 2006 | 19 | 0.060 |
Why?
| | Wasting Disease, Chronic | 1 | 2006 | 26 | 0.060 |
Why?
| | Granulocytes | 1 | 2006 | 80 | 0.060 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2015 | 1090 | 0.060 |
Why?
| | Lymphoid Tissue | 1 | 2006 | 75 | 0.060 |
Why?
| | Germany | 2 | 2024 | 121 | 0.060 |
Why?
| | Quality of Life | 3 | 2024 | 2878 | 0.060 |
Why?
| | Anti-Retroviral Agents | 1 | 2007 | 233 | 0.060 |
Why?
| | Interleukin-18 | 1 | 2007 | 236 | 0.060 |
Why?
| | Follicle Stimulating Hormone | 2 | 2023 | 244 | 0.060 |
Why?
| | Models, Psychological | 2 | 2018 | 302 | 0.060 |
Why?
| | Preoperative Period | 1 | 2025 | 129 | 0.060 |
Why?
| | Insulin Resistance | 1 | 2013 | 1203 | 0.060 |
Why?
| | Mutation | 1 | 2016 | 3946 | 0.060 |
Why?
| | Infant, Newborn | 4 | 2024 | 6033 | 0.060 |
Why?
| | Exercise Test | 2 | 2019 | 625 | 0.060 |
Why?
| | Sex Distribution | 2 | 2023 | 373 | 0.060 |
Why?
| | Mass Screening | 1 | 2013 | 1267 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2015 | 2046 | 0.050 |
Why?
| | Treatment Adherence and Compliance | 1 | 2024 | 26 | 0.050 |
Why?
| | Rehabilitation Centers | 1 | 2024 | 39 | 0.050 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2003 | 41 | 0.050 |
Why?
| | Algorithms | 1 | 2011 | 1689 | 0.050 |
Why?
| | Phototherapy | 1 | 2023 | 38 | 0.050 |
Why?
| | Hand Strength | 1 | 2024 | 122 | 0.050 |
Why?
| | Epidemiological Monitoring | 1 | 2024 | 60 | 0.050 |
Why?
| | Crisis Intervention | 1 | 2023 | 33 | 0.050 |
Why?
| | Neuroimaging | 2 | 2017 | 259 | 0.050 |
Why?
| | Follow-Up Studies | 4 | 2018 | 5106 | 0.050 |
Why?
| | Triamcinolone Acetonide | 1 | 2023 | 28 | 0.050 |
Why?
| | Multiple Trauma | 1 | 2024 | 100 | 0.050 |
Why?
| | Death Certificates | 1 | 2023 | 30 | 0.050 |
Why?
| | Calorimetry, Indirect | 1 | 2003 | 84 | 0.050 |
Why?
| | Global Burden of Disease | 1 | 2023 | 24 | 0.050 |
Why?
| | Transportation of Patients | 1 | 2023 | 54 | 0.050 |
Why?
| | Conserved Sequence | 1 | 2003 | 239 | 0.050 |
Why?
| | Hip Joint | 1 | 2024 | 171 | 0.050 |
Why?
| | Movement | 1 | 2025 | 272 | 0.050 |
Why?
| | Mood Disorders | 1 | 2023 | 129 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 1062 | 0.050 |
Why?
| | Regional Blood Flow | 1 | 2024 | 473 | 0.050 |
Why?
| | Accidental Falls | 1 | 2024 | 193 | 0.050 |
Why?
| | Personnel Turnover | 1 | 2022 | 40 | 0.050 |
Why?
| | Ohio | 1 | 2022 | 152 | 0.050 |
Why?
| | Needs Assessment | 1 | 2024 | 372 | 0.050 |
Why?
| | Infant | 3 | 2024 | 9398 | 0.050 |
Why?
| | Bacteremia | 1 | 2024 | 213 | 0.050 |
Why?
| | Meta-Analysis as Topic | 1 | 2022 | 186 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2007 | 895 | 0.040 |
Why?
| | Policy | 1 | 2022 | 149 | 0.040 |
Why?
| | Headache | 1 | 2022 | 147 | 0.040 |
Why?
| | Cause of Death | 1 | 2023 | 430 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 402 | 0.040 |
Why?
| | Cost of Illness | 1 | 2023 | 302 | 0.040 |
Why?
| | Postoperative Period | 1 | 2021 | 342 | 0.040 |
Why?
| | Testosterone | 2 | 2023 | 401 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2019 | 1981 | 0.040 |
Why?
| | Anxiety Disorders | 1 | 2023 | 374 | 0.040 |
Why?
| | Cervical Vertebrae | 1 | 2021 | 135 | 0.040 |
Why?
| | Internet | 1 | 2024 | 647 | 0.040 |
Why?
| | Administrative Claims, Healthcare | 1 | 2020 | 26 | 0.040 |
Why?
| | Job Satisfaction | 1 | 2022 | 216 | 0.040 |
Why?
| | Obesity | 1 | 2013 | 2982 | 0.040 |
Why?
| | Cardiovascular Deconditioning | 1 | 2019 | 5 | 0.040 |
Why?
| | Photophobia | 1 | 2019 | 10 | 0.040 |
Why?
| | Hyperacusis | 1 | 2019 | 8 | 0.040 |
Why?
| | Education, Graduate | 1 | 2020 | 34 | 0.040 |
Why?
| | Ribonucleases | 1 | 1999 | 55 | 0.040 |
Why?
| | Hypesthesia | 1 | 2019 | 17 | 0.040 |
Why?
| | Fee-for-Service Plans | 1 | 2020 | 85 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 556 | 0.040 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2019 | 13 | 0.040 |
Why?
| | Pain | 1 | 2024 | 754 | 0.040 |
Why?
| | Sleep | 2 | 2022 | 753 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2000 | 268 | 0.040 |
Why?
| | Rehabilitation | 1 | 2019 | 19 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2013 | 2518 | 0.040 |
Why?
| | Independent Living | 1 | 2020 | 105 | 0.040 |
Why?
| | Inhalation Exposure | 1 | 1999 | 105 | 0.040 |
Why?
| | Organizational Culture | 1 | 2020 | 146 | 0.040 |
Why?
| | Ethanol | 1 | 2023 | 606 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2019 | 328 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2020 | 549 | 0.040 |
Why?
| | Rhinitis | 1 | 1999 | 158 | 0.040 |
Why?
| | Disease Progression | 2 | 2016 | 2750 | 0.030 |
Why?
| | Bacterial Infections | 1 | 2000 | 250 | 0.030 |
Why?
| | Fetal Blood | 1 | 2000 | 327 | 0.030 |
Why?
| | Patient Admission | 1 | 2019 | 190 | 0.030 |
Why?
| | Reference Values | 1 | 2019 | 816 | 0.030 |
Why?
| | Emergency Medical Services | 1 | 2023 | 547 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2003 | 919 | 0.030 |
Why?
| | Regression Analysis | 2 | 2003 | 1022 | 0.030 |
Why?
| | Mobile Applications | 1 | 2020 | 182 | 0.030 |
Why?
| | Feedback | 1 | 2017 | 173 | 0.030 |
Why?
| | Self Care | 1 | 2020 | 375 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2019 | 267 | 0.030 |
Why?
| | Child, Preschool | 2 | 2024 | 11000 | 0.030 |
Why?
| | Prognosis | 2 | 2016 | 4013 | 0.030 |
Why?
| | Public Health | 1 | 2021 | 579 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 888 | 0.030 |
Why?
| | Organ Size | 1 | 2017 | 477 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2023 | 934 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2016 | 33 | 0.030 |
Why?
| | Wounds, Gunshot | 1 | 2019 | 220 | 0.030 |
Why?
| | Task Performance and Analysis | 1 | 2017 | 183 | 0.030 |
Why?
| | Amygdala | 1 | 2017 | 191 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2016 | 2022 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2000 | 572 | 0.030 |
Why?
| | Diet | 1 | 2023 | 1274 | 0.030 |
Why?
| | Air Pollution | 1 | 1999 | 315 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2016 | 59 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2020 | 656 | 0.030 |
Why?
| | Affect | 1 | 2018 | 292 | 0.030 |
Why?
| | Clone Cells | 1 | 2016 | 263 | 0.030 |
Why?
| | Psychological Tests | 1 | 2016 | 140 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 1999 | 549 | 0.030 |
Why?
| | Personal Construct Theory | 1 | 2015 | 5 | 0.030 |
Why?
| | Nevirapine | 1 | 2015 | 17 | 0.030 |
Why?
| | Zidovudine | 1 | 2015 | 78 | 0.030 |
Why?
| | Lamivudine | 1 | 2015 | 63 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 889 | 0.030 |
Why?
| | Drug Users | 1 | 2015 | 40 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 199 | 0.030 |
Why?
| | Reward | 1 | 2017 | 244 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 177 | 0.030 |
Why?
| | Gene Expression | 1 | 2000 | 1500 | 0.030 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 134 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 2015 | 269 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2024 | 1710 | 0.030 |
Why?
| | Neutropenia | 1 | 2015 | 146 | 0.030 |
Why?
| | Teaching Materials | 1 | 1994 | 23 | 0.030 |
Why?
| | Nursing Evaluation Research | 1 | 1994 | 47 | 0.030 |
Why?
| | Hospital Units | 1 | 2014 | 29 | 0.030 |
Why?
| | Demography | 1 | 2015 | 291 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 293 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 1 | 2015 | 114 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2022 | 1097 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2024 | 1798 | 0.030 |
Why?
| | Anemia | 1 | 2015 | 170 | 0.030 |
Why?
| | Research Design | 1 | 2020 | 1127 | 0.030 |
Why?
| | Patient Care Planning | 1 | 1994 | 157 | 0.030 |
Why?
| | Lipolysis | 1 | 2013 | 46 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2015 | 198 | 0.030 |
Why?
| | Curriculum | 1 | 2020 | 976 | 0.030 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2014 | 243 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 1935 | 0.020 |
Why?
| | Pregnancy | 2 | 2016 | 6728 | 0.020 |
Why?
| | Glucose Clamp Technique | 1 | 2013 | 195 | 0.020 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2013 | 159 | 0.020 |
Why?
| | Adolescent Health Services | 1 | 2013 | 71 | 0.020 |
Why?
| | Air Pollutants | 1 | 1997 | 427 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2016 | 535 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2012 | 307 | 0.020 |
Why?
| | Triglycerides | 1 | 2013 | 524 | 0.020 |
Why?
| | Aggression | 1 | 2012 | 200 | 0.020 |
Why?
| | Lung Diseases | 1 | 1997 | 767 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1481 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 605 | 0.020 |
Why?
| | Vital Capacity | 2 | 2000 | 311 | 0.020 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2007 | 38 | 0.020 |
Why?
| | Receptors, CCR5 | 1 | 2007 | 56 | 0.020 |
Why?
| | Lung | 1 | 2000 | 4052 | 0.020 |
Why?
| | Forced Expiratory Volume | 2 | 2000 | 531 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2007 | 111 | 0.020 |
Why?
| | Lewis X Antigen | 1 | 2006 | 4 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2007 | 388 | 0.020 |
Why?
| | Deer | 1 | 2006 | 32 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2008 | 271 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2007 | 318 | 0.020 |
Why?
| | Viral Load | 1 | 2007 | 464 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2006 | 396 | 0.010 |
Why?
| | Immune Sera | 1 | 1984 | 88 | 0.010 |
Why?
| | Body Mass Index | 1 | 2013 | 2375 | 0.010 |
Why?
| | Ovulation | 1 | 1984 | 40 | 0.010 |
Why?
| | Acute Disease | 1 | 2007 | 1004 | 0.010 |
Why?
| | Immunization, Passive | 1 | 1984 | 90 | 0.010 |
Why?
| | HLA-A3 Antigen | 1 | 2003 | 6 | 0.010 |
Why?
| | HLA-B7 Antigen | 1 | 2003 | 7 | 0.010 |
Why?
| | HLA-A2 Antigen | 1 | 2003 | 48 | 0.010 |
Why?
| | Superantigens | 1 | 2003 | 70 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2006 | 489 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 2003 | 126 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2007 | 1177 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 2003 | 145 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2007 | 1141 | 0.010 |
Why?
| | Blood Glucose | 1 | 2013 | 2181 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 2003 | 225 | 0.010 |
Why?
| | Gonadal Steroid Hormones | 1 | 1984 | 140 | 0.010 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2003 | 184 | 0.010 |
Why?
| | Basal Metabolism | 1 | 2003 | 61 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2006 | 1733 | 0.010 |
Why?
| | Brain | 1 | 2014 | 2664 | 0.010 |
Why?
| | Inflammation | 2 | 2006 | 2834 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 851 | 0.010 |
Why?
| | Leukocytes, Mononuclear | 1 | 2003 | 558 | 0.010 |
Why?
| | Nasal Lavage Fluid | 1 | 1999 | 14 | 0.010 |
Why?
| | Eosinophil Granule Proteins | 1 | 1999 | 21 | 0.010 |
Why?
| | Body Composition | 1 | 2003 | 679 | 0.010 |
Why?
| | Albumins | 1 | 1999 | 113 | 0.010 |
Why?
| | Nasal Mucosa | 1 | 1999 | 107 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1999 | 329 | 0.010 |
Why?
| | Biomarkers | 2 | 2000 | 4143 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2003 | 2160 | 0.010 |
Why?
| | Interleukins | 1 | 2000 | 250 | 0.010 |
Why?
| | Leukocytes | 1 | 1999 | 311 | 0.010 |
Why?
| | Blood Proteins | 1 | 1999 | 252 | 0.010 |
Why?
| | Urban Health | 1 | 1997 | 92 | 0.010 |
Why?
| | Eosinophils | 1 | 1999 | 332 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2000 | 1059 | 0.010 |
Why?
| | Linear Models | 1 | 1997 | 846 | 0.010 |
Why?
| | Animals | 3 | 2006 | 36823 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2000 | 2831 | 0.010 |
Why?
| | Students | 1 | 1997 | 622 | 0.010 |
Why?
| | Mice | 1 | 2003 | 17733 | 0.000 |
Why?
| | Androstenedione | 1 | 1984 | 11 | 0.000 |
Why?
| | Estrone | 1 | 1984 | 37 | 0.000 |
Why?
| | Sheep | 1 | 1984 | 856 | 0.000 |
Why?
| | Estradiol | 1 | 1984 | 518 | 0.000 |
Why?
|
|
Forster's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|